Immucor Inc. (BLUD:NASDAQ)

Immucor Inc. expected to Report Q2 2010 Results on January 4, 2010. This event was calculated by Capital IQ (Created on October 2, 2009).

Immucor Inc. reported unaudited consolidated financial results for the first quarter ended August 31, 2009. For the quarter, the company's revenue was $83.1 million, an increase of approximately $9.9 million or 14% over $73.17 million for the first quarter of fiscal 2009. Revenue in the quarter benefited from both price and volume contributions. Revenue in the quarter as compared with the first quarter of fiscal 2009 was negatively impacted by approximately $1.7 million due to fluctuations in foreign currency exchange rates. The company reported income from operations of $33.34 million, income before income taxes of $33.56 million, cash provided by operating activities of $24.53 million, purchases of property and equipment of $3.55 million and net income of $21.33 million or $0.30 per diluted share compared to income from operations of $30.62 million, income before income taxes of $30.87 million, cash provided by operating activities of $21.56 million, purchases of property and equipment of $1.84 million and net income of $19.95 million or $0.28 per diluted share for the same period a year ago. The company continues to expect fiscal 2010 consolidated revenue in the range of $322 million to $332 million and consolidated gross margins in the range of 70.0% to 71.5%. The company continues to expect diluted earnings per share to be in the range of $1.10 to $1.17 for fiscal 2010, which includes the approximately $0.04 per share impact, net of tax, related to the Quality Process Improvement Project. The company's fiscal 2010 guidance also includes a full year of BioArray expenses. The company continues to expect to launch the next generation automated instrument, the Galileo Neo(TM) in the first calendar quarter of 2010.

Immucor Inc., Annual General Meeting, Nov 12, 2009, at 13:30 US Eastern Time. Location: 3150 Gateway Drive, Norcross, GA 30071,United States. Agenda: To elect seven directors to each serve until the company's next annual meeting of shareholders, or until their respective successors are duly elected and qualified; to ratify the appointment of Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending May 31, 2010; to approve the amendment to the Amended and Restated Rights Agreement between the company and Computershare Trust Company N.A. as rights agent; to transact such other business as properly may come before the meeting or any adjournment thereof.